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Abstract: Historically, cell-signaling pathways have been studied as the compilation of 
isolated elements into a unique cascade that transmits extracellular stimuli to the tumor cell 
nucleus. Today, growing evidence supports the fact that intracellular drivers of tumor 
progression do not flow in a single linear pathway, but disseminate into multiple 
intracellular pathways. An improved understanding of the complexity of cancer depends on 
the elucidation of the underlying regulatory networks at the cellular and intercellular levels 
and in their temporal dimension. The high complexity of the intracellular cascades causes 
the complete inhibition of the growth of one tumor cell to be very unlikely, except in cases 
in which the so-called “oncogene addiction” is known to be a clear trigger for tumor 
catastrophe, such as in the case of gastrointestinal stromal tumors or chronic myeloid 
leukemia. In other words, the separation and isolation of the driver from the passengers is 
required to improve accuracy in cancer treatment. This review will summarize the 
signaling pathway crossroads that govern renal cell carcinoma proliferation and the 
emerging understanding of how these pathways facilitate tumor escape. We outline the 
available evidence supporting the putative links between different signaling pathways and 
how they may influence tumor proliferation, differentiation, apoptosis, angiogenesis, 
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metabolism and invasiveness. The conclusion is that tumor cells may generate their own 
crossroads/crosstalk among signaling pathways, thereby reducing their dependence on 
stimulation of their physiologic pathways.  
Keywords: human renal cell carcinoma (hRCC); signaling pathway crosstalk; biomarkers 
 
1. Introduction 
Knowledge continues to increase regarding the intracellular cascades that govern the growth and 
spread of tumor cells. In recent decades, we have tried to inhibit tumor growth by selectively blocking 
the beginning of the cascade at the receptor level (such as in the use of anti-epidermal growth factor 
receptor (EGFR) inhibitors), blocking the middle of the cascade (such as with anti-RAF or anti-mTOR 
inhibitors) or blocking extracellular ligands (such as vascular endothelial growth factor (VEGF)) 
before contact with the transmembrane receptors expressed on tumor cells. Success in terms of a clear 
change in the natural history of the cancer is not frequently seen. We have only achieved long-term 
responses and stabilization of the disease in tumors in which a well-defined trigger starts the 
proliferation cascade, such as in the case of gastrointestinal stromal tumors (GIST) or chronic myeloid 
leukemia (CML). Even in these cases, curing the disease is not yet a realistic objective.  
The barriers to cancer development are embodied in an ontogeny; cancer cells have defects in 
regulatory intracellular circuits that govern proliferation and homeostasis. The most complex 
mechanisms of acquired cancer cell autonomy derive from alterations in components of the 
downstream cytoplasmic circuitry that receives and processes the signals emitted by ligand-activated 
receptors.  
These complex biological systems can be thought of as scale-free networks with an uneven 
distribution of connections to key signaling nodes. Signals downstream of pathways and other signals 
interact in a number of significant ways in the tumor tissues, acting in either a synergistic or 
antagonistic manner. Although some findings on pathway interaction may turn out to be cell  
type-specific, a general synthesis of the present state of knowledge can be attempted. 
Unfortunately, signaling cascades are not linear and frequently interact, generating short-circuits 
between different intracellular pathways and increasing the complexity of the system. This complexity 
provokes many questions that are not yet understood.  A fundamental paradigm in modern oncology is 
the discovery of biologically relevant pathways on which cancer cells rely for survival. This paradigm 
depends on multiple factors, including the identification of pathways that are truly critical for cell 
survival. Deciphering the added value of these and other signaling pathways will require a careful 
assessment of the risk and benefit of each pathway across different patient phenotypes.  
Much remains to be learned about pathway crossroads as targets in human cancer with regard to 
inhibition with optimal risk/benefit ratios and the identification of novel targets for cancer therapy. The 
investigation of gene and protein expression will hopefully provide insight leading to the optimization 
of specific therapies for specific tumors. Translational investigation is needed to identify the molecular 
phenotypes associated with response and resistance to each of the agents. 
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This review provides a kaleidoscopic view of the last two decades of development in this field and 
the interactions between different cell pathways.  
2. Signaling Pathways in hRCC 
2.1. The Von Hippel-Lindau (VHL) Pathway 
Von-Hippel-Lindau disease is a rare, autosomal dominant, familial cancer syndrome that manifests 
as retinal angiomas, hemangioblastomas of the central nervous system, pheochromocytomas and  
clear-cell renal carcinomas (ccRCC) [1]. VHL is caused by an inherited mutation of one allele of the 
VHL tumor suppressor gene located on chromosome 3q25-26 [2]. Associated focal lesions (e.g., renal 
cell carcinoma) are caused by inactivation or silencing of the remaining wild-type VHL allele. In 
sporadic clear cell renal carcinomas, VHL gene defects are common (60%–75%), and up to 20% of 
tumors exhibit decreased VHL expression due to hypermethylation [3–7]. Whether sporadic renal cell 
carcinoma (RCC) prognosis is related to the type of VHL mutation or altered expression is unclear. 
The VHL gene functions in the hypoxia-inducible pathway and the VHL gene product are a component 
of a multi-protein complex (consisting of Elongin B and C, Cul2, and Rbx1) that ubiquitinates the 
transcriptional factor hypoxia-inducible factor (HIF)-1α [8]. The Hypoxia-inducible factor (HIF)-1 
complex, a heterodimer containing an α and β subunit, responds to hypoxic stress to regulate the 
expression of several genes, including VEGF, EGFR, platelet-derived growth factor (PDGF), glucose 
transporters (such as GLUT-1), transforming growth factor-α (TGF-α) and erythropoietin (EPO) [9,10]. 
VHL loss-of-function mutations prevent ubiquitin-mediated HIF-1α degradation, causing the 
upregulation of hypoxia-inducible genes. Growth factor and adhesion pathways (e.g., the  
RAS-mitogen activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase 
(PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway) also regulate HIF-1α activity. In 
addition to HIF-1α, VHL binds to the cell-matrix protein fibronectin, the chaperonin TRiC/CCT, 
microtubules, and the transcription factor Jade-1, suggesting that these proteins also contribute to 
disease pathogenesis [1]. 
The two most important pathways in ccRCC are those governed by pVHL (Von Hippel-Lindau 
protein) and mammalian target of rapamycin complex 1 (mTORC1). It has been discovered that the 
REDD1 protein links these pathways [11]. 
2.2. The Notch Signaling Pathway  
In recent years, Notch has emerged as a critical element in kidney development. Accumulating 
evidence suggests that Notch signaling plays a critical role in survival, proliferation, and cell fate at 
various stages of kidney development, including in the decision by kidney side population (SP) cells to 
self-renew or differentiate [12–14]. Although the existence of resident stem cells in the mature 
mammalian kidney has not been proven, SP cells in the adult kidney have been proposed to represent a 
progenitor population. The modulation of Notch signaling at various levels, including at the level of 
ligand expression, has provided evidence of the influence of this pathway. 
A survey of the list of genes that are strongly expressed in kidney SP highlights many members of 
the Notch signaling pathway, including the receptors Notch1, Notch2, and Notch3, the ligands Jagged1 
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and Jagged2, the secreted protein radical fringe gene homologue (Rfng), the intracellular signaling 
molecules Deltex2 (Dxt2) and Deltex3 (Dxt3), the transcriptional regulators transducin-like enhancer 
of split (Tle1) and Riken (CBF1 interacting corepressor) and the noted Notch target genes Gsk3b [15] 
and cyclins D1 and E1 [16]. 
Notch1 and the Notch ligand Jagged1 are expressed at significantly higher levels in ccRCC tumors 
than in normal renal tissue [10]. The expression of Notch receptors has been shown to be deregulated 
in RCC. The expression levels of Notch1 and Notch 4 are significantly decreased in human renal cell 
carcinoma tissues as compared with adjacent non-neoplastic tissues.  Notch1 and Notch4 are also 
markedly down-regulated in human renal cell cancer cell lines. In contrast, Notch2 and Notch3 
expression is minimally detected [17]. 
2.3. The HIF Pathway 
The hypoxia pathway (HIF) is crucial during developmental organogenesis and in several adult 
pathologies, such as cancer.  
To maintain the appropriate level of ATP that is required for proper cellular metabolism, the 
oxygen concentration must be closely monitored [18]. During normoxia, the VHL tumor suppressor 
targets the hypoxia-inducible factor HIF-1α for ubiquitination and proteasomal degradation. In 
response to hypoxia, stabilized HIF-1α and HIF-2α proteins bind HIF-1β and initiate expression of 
genes that alleviate hypoxic stress, including those promoting neovascularization. Both HIF-1 and 
HIF-2 stimulate transcription of VEGF, a crucial regulator of vascular development. Tight regulation 
of the stability and subsequent transactivational function of HIF-1α is chiefly controlled by its  
post-translational modifications, such as hydroxylation, ubiquitination, acetylation, and phosphorylation. 
For example, HIF-1α uniquely stimulates the expression of glycolytic enzymes, such as 
phosphoglycerate kinase and lactate dehydrogenase-A, carbonic anhydrase-9, and the pro-apoptotic 
gene BNIP-3 [19–22]. In contrast, under hypoxia, HIF-2α up-regulates CYCLIN D1, TFG-α, and  
EPO [21,23–26]. A third group of genes, VEGF, and GLUT1 are regulated by both α subunits [19,27]. 
These genes contain a hypoxia response element (HRE) in their regulatory sequences to which the 
HIF dimer binds. Overall, the activation of such hypoxia target genes enables cells to respond to 
oxygen deprivation by controlling angiogenesis, cell growth, and metabolism [28]. 
HIF-1α induces the expression of transforming growth factor α, with consequent activation of the 
epidermal growth factor receptor (EGFR)/phosphatidylinositol-3-OH kinase (PI3K)/protein kinase B 
(AKT)/IkB-kinase α (IKKα)/NF-kB signaling cascade [29]. 
HIF-2α stabilization can be observed by immunohistochemistry in renal interstitial cells [30].  
HIF-2α is stabilized in von Hippel-Lindau (VHL)-deficient renal cell carcinoma through mechanisms 
that require ongoing mRNA translation. mTOR functions in two distinct complexes: Raptor-associated 
mTORC1 and Rictor-associated mTORC2. HIF-2α is frequently expressed in solid tumors. The role of 
HIF-2α in the pathogenesis of ccRCC has been the most extensively studied.  
Activation of an autocrine signaling loop through TGF-α-mediated stimulation of the EGFR has 
been proposed to drive the serum-independent growth of renal carcinoma cells [25,31]. 
HIF-2α may also play a role in renal carcinomas caused by mutations in the tumor suppressor 
tuberous sclerosis-2 (Tsc-2) [32]. 
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HIF-1α expression is low in 76% of RCC, and only 25% of patient samples display moderate to 
high staining. HIF-1α expression tends to be associated with better prognosis and might be less 
important than HIF-2α expression in human RCC [33]. 
Renal cell carcinoma, as is the case in many cancers, demonstrates oxidative stress. An interplay 
between hypoxia pathway and mTORC1 is that reactive oxygen species, such as hydrogen peroxide, 
activate AMP-activated protein kinase (AMPK)-alpha to inhibit mTORC1 signaling [34]. 
2.4. The VEGF Pathway  
Six secreted glycoproteins comprise the VEGF-related gene family of angiogenic and 
lymphangiogenic growth factors, including VEGF-A (commonly referred to as VEGF), VEGF-B, 
VEGF-C, VEGF-D, VEGF-E and placenta growth factor (PIGF)-1. VEGF is an endothelial  
cell-specific mitogen in vitro and an angiogenic inducer of arteries, veins and lymphatic vessels  
in vivo [35–39]. As a pleiotropic growth factor, VEGF mediates multiple functions, including the 
regulation of vessel permeability, endothelial cell activation, survival, proliferation, invasion and 
migration. VEGF is implicated in developmental, reproductive, bone and pathological  
angiogenesis [37–40]. Located on chromosome 6p21.3, the human VEGF-A gene is organized into 8 
exons and 7 introns [41]. The receptor tyrosine kinase FLT-1 (fms-like tyrosine kinase, VEGFR-1) and 
Flk-1/KDR (VEGFR-2) are high-affinity VEGF receptors. VEGF also interacts with neuropilins  
NP-1/2, a family of co-receptors [42,43]. VEGFR-3 is another member of the VEGFR-family that 
binds VEGF-C and D but not VEGF. VEGFR-2 mediates the majority of VEGF down-stream 
angiogenic effects, while VEGFR-1 is critical in developmental angiogenesis [37–39]. 
Tumor-associated stroma is another important site of VEGF production. VHL inactivation, which 
mediates the over-expression of VEGF in approximately 80% of ccRCC patients, causes VEGF and its 
receptor to be interesting targets for novel RCC treatment strategies [37–39]. 
A potential crosstalk of VEGF and MAPK in RCC angiogenesis is that VEGFR-3-mediated ERK 
signaling pathway contributes to lymphangiogenesis based on recent report [44]. 
2.5. The Epidermal Growth Factor Receptor (EGFR) Pathway 
RCCs frequently show EGFR immunoreactivity [45,46] that is primarily localized to the cell 
membrane. In contrast, EGFR expression in normal renal tissues is chiefly observed in the cytoplasm. 
Previous studies have shown that up-regulation of EGFR is one of the common events in RCC 
tumorigenesis [47]. Over-expression of EGFR is thought to play an important role in the initiation and 
progression of RCC because up-regulation of EGFR has been associated with high tumor grade and 
worse prognosis [48,49]. 
Studies characterizing the localization of EGFR have shown that EGFR has membranous and 
cytoplasmic expression. EGFR membranous staining is significantly stronger in RCC tumors than in 
normal tissues. In contrast, EGFR cytoplasmic staining is significantly higher in normal than in tumor 
tissues [50]. The different locations of EGFR immunostaining may be associated with progression and 
prognosis in RCC [51,52]. A significant correlation also exists between the level of membranous 
EGFR expression and the histologic subtypes, with higher expression in conventional RCC than  
non-conventional RCC (including papillary, chromophobe, sarcomatoid, and collecting duct  
Int. J. Mol. Sci. 2012, 13             
 
12715
subtypes) [50]. Previous studies have indicated that cytoplasmic EGFR immunostaining is associated 
with higher tumor stage and grade and poor prognosis in RCCs [51,52]. However, the prognostic value 
of EGFR over-expression in RCC is a controversial issue. Some studies have shown an association 
between EGFR immunoreactivity and well-differentiated RCCs [52,53], whereas others have shown 
an association between EGFR immunoreactivity and high tumor stage/grade and poor prognosis [54] 
or no significant association at all [55]. 
Other studies have suggested the existence of a novel role for the EGFR signaling pathway, in 
which activated EGFR undergoes nuclear translocation and subsequently regulates gene expression to 
potentially mediate specific cellular processes [56,57]. This new role of EGFR is distinct from the 
well-known traditional EGFR signaling that involves the transduction of mitogenic signals through the 
activation of multiple signaling cascades. 
Signaling through EGFR has been shown to result in NF-kB activation, and EGFR-mediated 
activation of NF-kB can occur in a PI3K/AKT-dependent manner in clear cell RRCs that constitutively 
express HIF-1α as a consequence of biallelic VHL loss [29]. 
Phosphorylation of the eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) is 
abrogated by inhibition of the mTORC1, comprised of TOR, Raptor, and LST8, which is highly 
sensitive to inhibition by rapamycin [58]. Inhibition of mTORC1 is intricately regulated by the 
tuberous sclerosis Tsc-1/Tsc-2 protein complex [58]. Germline mutations in the Tsc-1 and Tsc-2 genes 
result in alterations in cell growth, survival, proliferation, migration, differentiation and  
angiogenesis [59]. The gene products of Tsc-1 (harmartin) and Tsc-2 (tuberin) form a heterodimeric 
protein complex that negatively regulates the mTOR signaling pathways [60]. Loss of tuberin 
expression results in increased levels of Rheb-GTP and subsequently activation of mTOR.  
Rheb-GTP/mTOR signaling has been implicated in tumor development, via its downstream 
modulation of protein synthesis, cell proliferation, cell cycle progression, and cell survival [58]. 
The Rafs regulate cellular proliferation and differentiation through the Raf/MEK/ERK/MAPK 
signaling cascade, which is hyperactivated in ~30% of all cancers [61]. In an in vitro kinase assay, 
recombinant 4EBP1 was a substrate for ERK/MAPK, suggesting that ERK may play a role in the 
hierarchical phosphorylation of 4EBP1. The loss of heterozygosis in the Tsc-2 gene and subsequent 
loss of tuberin expression observed in TGHQ-induced renal tumors [62], and tumorigenic QTRRE 
cells [63], makes this a unique model to study the role of constitutive Raf/ERK MAPK in  
tuberin-deficient renal carcinogenesis. 
The study of the relationship between tuberin, the B-Raf/Raf-1/ERK MAPK cascade, and 4EBP1 
hyperphosphorylation identified Raf-1 as an effective regulator of 4EBP1 phosphorylation and 
activator of cap-dependent translation during renal carcinogenesis. Inhibition of either the MAPK or 
mTOR pathway alone is insufficient to abrogate 4EBP1 phosphorylation because both mTOR and 
ERK are capable of modulating phosphorylation of 4EBP1 in renal proximal tubule cells [64]. 
2.6. The CAIX Pathway 
Carbonic anhydrases (CA) are metalloenzymes that catalyze the reversible hydration of carbon 
dioxide to form bicarbonate and protons. The first reaction is catalyzed by carbonic anhydrase, and the 
second reaction occurs instantaneously. 
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In mammals, 16 different α-CA isoenzymes or CA-related proteins (CARP) have been described 
with very different catalytic activities and sub-cellular localizations. Some of these proteins are 
cytosolic (CA I, CA II, CA III, CA VII, and CA XIII), others are membrane-bound (CA IV, CA IX, 
CA XII, CA XIV, and CA XV), one is mitochondrial (CA Va and CA Vb) and one (CA VI) is secreted 
in saliva and milk. The different CAs have different tissue distributions, subcellular localizations, 
biological functions and kinetic properties [65]. 
Carbonic anhydrase IX (CA IX), or MN protein, consists of a signal peptide, a proteoglycan-related 
sequence, an enzymatically active extracellular carbonic anhydrase domain, a transmembrane segment 
and a short intracellular tail. CA IX is one of four transmembrane isoenzymes and has been implicated 
in the control of cell proliferation and cellular transformation [66]. 
CA IX overexpression has been identified in renal carcinoma, particularly clear cell 
adenocarcinoma [67]. CA IX has been well recognized to be a sensitive and specific marker of the 
clear cell histotype and is absent in papillary type, chromophobe and oncocytoma tumors [68–71].  
RT-PCR analysis in benign and malignant renal tissue has demonstrated that the expression of CA IX 
is limited to ccRCC [72]. 
The expression of CA IX in advanced ccRCC has been described as an independent predictor of 
survival; decreased expression of CA IX portends a worse prognosis in patients with a metastatic clear 
cell histotype [73].  
The fact that lower expression of CA IX is observed in metastatic lesions than in the corresponding 
primary tumor suggests that as tumors progress, they becomes less dependent on hypoxia-inducible 
factors and possibly become increasingly driven by mutations that control other pathways [74]. 
2.7. The GLUT 1-5 Transporters Pathway 
Glucose metabolism is a central component of living systems. The oxidation of glucose represents a 
major source of metabolic energy for mammalian cells. However, tumor cells have a reduced capacity 
to use oxidative metabolism and rely instead on an increased rate of glycolysis and glucose  
utilization [75]. Increased active glycolytic metabolism is reflected in an increased rate of glucose 
uptake [76]. The increase in glucose uptake by malignant cells is currently accepted to be associated 
with the overexpression of glucose transporters (GLUTs). In malignant cells, this process is mediated 
by GLUTs, whose expression and activity is regulated by oncogenes and growth factors [77]. An 
increase in glucose transport and metabolism may reflect a requirement by these rapidly growing cells 
for additional sources of energy [78].  
GLUT5 is over-expressed in most RCCs, but previous studies have shown that GLUT1 displays the 
highest expression in RCCs [79]. The elevated expression of GLUT5 could indicate a preferential 
utilization of fructose in RCC. This fructose utilization can be associated with the tumors’ need for an 
additional energy source.  
Cancer cells maintain a high rate of glycolysis, even in the presence of oxygen  
(Warburg effect) [80], probably due to the utilization of fermentative metabolism under the hypoxic 
conditions that develop in more aggressive tumors. GLUT5 over-expression may allow an increase in 
fructose uptake and, conversely, the increase in fructose utilization in the tumor cells may lead to 
GLUT5 over-expression. 
Int. J. Mol. Sci. 2012, 13             
 
12717
2.8. The p53 Pathway  
p53 is a known inducer of apoptosis, and the prognostic significance of p53 in RCC remains 
controversial [81–84]. A wide variation in the incidence of p53 mutations has been reported in RCC, 
and the prognostic significance of p53 mutations for this tumor is unknown. Some authors have 
reported that p53 mutations in RCC cases might be used as a prognostic factor, and they believe that 
over-expression of the mutant p53 protein reflects the potential that genetic instability might have 
already occurred. In contrast to these reports, some studies have demonstrated that p53 mutations have 
no value in predicting prognosis in RCC [81,82,85]. 
RCC rarely acquires mutations in the p53 tumor suppressor gene (3% to 33%), suggesting that p53 
signaling in this tumor type might be repressed by other mechanisms [86]. Loss of p53 function is a 
critical event in the evolution of a tumor. This loss occurs through a range of molecular events, 
typically a missense p53 mutation followed by loss of heterozygosity. 
Although the best-studied mechanisms of p53 regulation are post-transcriptional [87], a  
less-appreciated (but nevertheless important) form of p53 regulation is at the level of p53  
transcription [88]. Recent studies have revealed that activation of Stat3 is associated with RCC 
progression and poor survival [89], while p53 induces apoptosis in renal tumor cells [90]. 
Also, signal transducer and activator of transcription Stat3 and p53 have been shown to integrate 
upstream signals and to be positive and negative regulators, respectively, of tumor cell proliferation. 
Stat3 and p53 also negatively regulate each other. These findings suggest that Stat3 and p53 are 
cooperatively involved in the development of RCC [91,92]. 
p53-independent apoptosis in RCC may due to regulation of MAPK pathway according to current 
research in a panel of tumor cells with mutant p53 [93]. 
2.9. The Transforming Growth Factor-β (TGF-β) Pathway 
TGFs are peptides that reversibly promote anchorage-independent growth. The importance of  
TGF-β stems from the fact that it contributes to apoptosis control, angiogenesis, wound healing, 
immune regulation and tumor biology. TGF-β binds to the type II receptor, which then recruits and 
phosphorylates the type I receptor within its cytoplasmic domain [94]. The activated type I receptor 
then phosphorylates cytoplasmic substrates (the Smad proteins), which subsequently form complexes 
that translocate to the nucleus, thereby regulating the transcription of target genes [95].  
Evidence for the critical role of TGF-β type I and type II receptors in TGF-β signaling and control 
of cell growth has been provided by studies of human neoplasia in which mutations in both type I and 
II TGF-β receptors are observed [96]. Reduced expression of the TGF-β type II receptor has been 
observed in RCC [97]. 
Signals from the activated TGF-β receptor complex are transduced to the nucleus by Smad proteins, 
a family of transcription factors [98]. To date, the Smads are the only TGF-β receptor substrates with a 
demonstrated ability to propagate signals. Reduced Smad2 and Smad4 expression has been observed in 
RCC. Reduced Smad2 expression in RCC correlates with a higher tumor grade, which is indicative of 
a more aggressive tumor [99]. 
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TGF-β inhibits the proliferation of renal tubular epithelial cells and glomerular mesangial cells. 
TGF-β1 most likely inhibits cell growth by regulating the assembly and activity of cyclin-dependent 
kinase (cdk) complexes, which are necessary for cell-cycle progression from G1 to S phase [95,100,101]. 
In addition, TGF-β is clearly a master regulator of the immune response, and it exerts inhibitory 
effects on cells of all arms of the immune system, including Th1 cells, Th2 cells, CTLs, macrophages, 
NK cells, B cells and polymorphonuclear leukocytes (granulocytes). Importantly, TGF-β stimulates 
the production of connective tissue growth factor (CTGF), endothelin-1 and VEGF [102,103]; these 
factors collaborate in promoting the formation of a vascular and fibrous tumor stroma. Moreover, 
TGF-β attracts macrophages and other inflammatory cells to the stroma, and these cells secrete various 
mediators and growth factors that sustain tumor progression [104]. 
Upon tumor progression, TGF-β becomes a tumor promoter and induces an epithelial-to-
mesenchymal transition (EMT) through Smad-dependent and Smad-independent pathways. EMT is 
associated with increased secretion of matrix metalloproteinases, which promote tumor intravasation 
or extravasation. The effects of TGF-β on EMT, tumor growth or metastasis can be dissociated and 
might depend on different signaling pathways [105–107]. See schematics Figures 1 and 2. 
Figure 1. Schematic representation of selected signaling pathways in renal cell carcinoma 
(RCC). Angiogenic and cell proliferating signaling cascades are upregulated in RCC tumor 
cells. The vascular endothelial growth factor (VEGF) and other related growth factors 
secreted by tumor cells stimulate angiogenic signaling in the surrounding vascular 
endothelial cells. In response to growth factor signaling mediated through VEGF,  
platelet-derived growth factor (PDGF), and KIT receptors, PI3-kinase and Ras effectors 
activate hypoxia pathway (HIF) transcription factors, which in turn switch on gene 
expression needed for angiogenesis and cell proliferation in endothelial cells. In addition to 
the angiogenic pathway, the Wnt pathway is also upregulated in RCC tumor cells. 
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Figure 2. Nuclear targets of selected signaling pathways in RCC. 
 
2.10. The Transforming Growth Factor-α (TGF-α) Pathway 
RCC produces cytokines, including transforming growth factor-alpha (TGF-α) [108,109], 
interleukin-6 (IL-6) [110], EGF [111], and insulin-like growth factor. Among these growth factors, 
TGF-α and IL-6 are produced at very high levels in RCC cells, suggesting that they play an important 
role in the proliferation of RCC. 
3. Pathway Crosstalk 
3.1. Crosstalk between the Notch Pathway and HIF Signaling 
Hypoxia upregulates the expression of Notch targets. This upregulation might occur through the 
direct interaction with and the stabilization of Notch intracellular domain (NIC) by HIF-1α and/or by 
recruiting transcriptional coactivators [112]. Ultimately, the HIF-1α-NIC heterodimer binds to the 
promoters of Notch targets and synergistically increases transcription of genes involved in tumor 
progression and angiogenesis. Interestingly, hypoxia appears to enhance the stability of intracellular 
Notch.  
Hypoxia induces the expression of the endothelial cell-specific Notch ligand Delta4, leading to 
increased Notch signaling [113,114]. 
Conversely, tumor hypoxia is a known link to increased metastatic potential, and Notch signaling is 
required to convert the hypoxic stimulus into an EMT, increased motility and invasiveness.  
Hypoxia-induced increased motility and invasiveness requires Notch signaling, and activated Notch 
mimics hypoxia in the induction of EMT. In this process, Notch signaling controls Snail-1 expression 
by two distinct but synergistic mechanisms [115]. 
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3.2. Crosstalk between the Notch Pathway and EGFR Signaling 
The tumor suppressor function of γ-secretase has been implicated in the mechanism that links the 
EGFR pathway and the Notch pathway. Notch is a well-recognized substrate of γ-secretase [116,117], 
and a reduction in γ-secretase activity results in altered Notch signaling by affecting the level of the 
transcription factor Hes1, a direct target gene that is up-regulated by Notch signaling. 
Up-regulation of EGFR is dependent on the levels of γ-secretase activity, and a reduction in  
γ-secretase leads to up-regulation of EGFR. Therefore, the levels of EGFR appear to be inversely 
related to the levels of γ-secretase. 
Consistent with these findings, whereas Notch signaling reduces EGFR activation, the  
up-regulation of EGFR is independent of Notch signaling, indicating that the EGFR pathway 
regulation by γ-secretase functions in parallel with Notch in tumorigenesis. Up-regulation of EGFR 
results from the down-regulation of Notch signaling.  
Taken together, the activation of EGFR in parallel with altered Notch signaling plays a critical role 
in the tumor suppressor function of γ-secretase. 
3.3. Crosstalk between the Notch Pathway and VEGF Signaling 
Accumulating evidence has shown the intricate link between Notch activation and VEGF signaling. 
VEGF can induce the expression of Notch receptors and Dll4. Dll4 can reduce the expression of 
VEGFR-2 in endothelial cells (ECs), contributing to the feedback regulation of VEGF. Notch 
receptors have been shown to regulate the expression of endothelial VEGFRs [118]. 
Several studies have suggested that VEGF induces the expression of the Notch receptor via the 
PI3K-Akt pathway in human arterial endothelial cells to trigger Notch signaling, which plays a critical 
role in vascular formation during early embryonic development by activating the angiogenic  
process [119].  
Notch induces VEGFR-3 expression in vitro in human endothelial cells and in vivo in mice [120]. 
The Notch/CBF1/suppressor of hairless/Lag-2 (CSL) complex binds and transactivates the VEGFR-3 
promoter, providing evidence that the VEGFR-3 gene is a direct transcriptional target of Notch. 
Through induction of VEGFR-3, Notch signaling causes endothelial cells to become more responsive 
to VEGF-C (a VEGFR-3 ligand) and promotes endothelial cell survival and morphological changes. 
VEGF-C can bind and activate both VEGFR-2 and VEGFR-3, but Notch-mediated endothelial cell 
survival is most likely to occur via VEGFR-3 because VEGFR-2 expression is downregulated  
by Notch. 
3.4. Crosstalk between the Notch Pathway and p53 Signaling 
Crosstalk between the Notch pathway and the p53 pathway can occur at multiple levels in a manner 
that is dependent on the overall network organization of the individual cell types or tissues in which 
they operate [121–126]. Notch signaling can either suppress or increase p53 activity in a  
context-dependent manner that is closely connected to tumor promotion or suppression. Overall, the 
contexts in which Notch signaling restricts growth and/or induces apoptosis have been frequently 
linked with positive regulation of p53 activity and expression. 
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Notch activation has been shown to increase cell survival through the activation of the PI3K-Akt 
pathway, which leads to increased murine double minute 2 (MDM2) activity and consequent p53 
degradation [127,128]. A second key function of Notch in transformation is the suppression of 
apoptosis through down-modulation of p53 [129]. 
In contrast, p53 can be positively affected in systems in which Notch activation exerts a  
growth-inhibitory or pro-apoptotic function (i.e., cervical carcinoma).  
Notch and p53 are both expressed in RCC. Therefore, crosstalk between the pathways may exist at 
multiple levels, such that Notch and p53 can interact either positively or negatively depending on the 
cell type and stage of the cancer [130]. Notch signaling can regulate p53 activity, but p53 can also 
regulate Notch; these reciprocal positive or negative feedback loops are important for cell proliferation 
and cancer development [131]. 
Cross-regulation between the Notch and p53 pathways may also occur further down-stream, at the 
level of shared intermediates (i.e., the transcriptional co-activator mastermind-like1 (MAML1)) 
[132,133] or an endocytic protein (NUMB) [134]. 
4. Conclusions  
4.1. The Backbone of Intracellular Crosstalk 
Each of the physiologic changes in the previously mentioned intracellular pathways represents the 
successful breaching of an anticancer defense mechanism that is hardwired into cells. This multiplicity 
may explain why cancer acquires autonomy and is largely due to the prevalence of dominant 
oncogenes that have been found to modulate tumor development. We suspect that the crosstalk 
between signaling pathways is deregulated in all human tumors. Although this point is difficult to 
prove rigorously the clues are abundant, and the appearance of secondary mutations, overexpression of 
other transmembrane receptors or activation of parallel intracellular pathways is frequently observed in 
oncology. We suggest that tumors may carry defects in many components of the signaling pathways. 
The nature of these alternative mechanisms for cell survival remains elusive. Under intensive study 
over years, the wiring diagram of the signaling circuitry crossroads in mammalian cells is coming into 
focus. New downstream signaling pathways that radiate from the cell membrane through the 
cytoplasm to the nucleus are being discovered with some regularity. These cascades are linked via a 
variety of cross-talking connections with other pathways, and these cross-connections enable 
extracellular signals to elicit multiple biological effects. The acquisition of crossroad signaling 
autonomy by cancer cells is conceptually satisfying. However, it is increasingly apparent that the 
deregulation of crossroads within a tumor cell can only be explained once we understand the 
contributions of the ancillary signaling pathways present in a tumor, which must play key roles in 
driving tumor cells. Heterotypic signaling inside the diverse cell types within a tumor may ultimately 
prove to be as important for explaining tumor cell proliferation. We suspect that many of the crossroad 
signals driving the proliferation of cancer cells originate from the cell components of the individual 
tumor cells.  
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4.2. The Hyper-Network Concept 
Cells rely on a handful of core signaling pathways to guide a wide range of developmental 
processes, from the earliest specification events to more complex specialization functions. To achieve 
the morphological complexity that is characteristic of mammalian cells, these core signaling pathways 
must integrate to form a larger, complex signaling system, which we term the “hyper-network.” 
However, comprehensive knowledge of this network, the nodes that define it and its emergent 
properties are lacking. Studying how these highly pleiotropic pathways are interlinked is essential to 
understand development and evolution and, consequently, defines a fundamental problem in biology 
with obvious implications for cancer. 
Because multiple mechanisms interlink diverse signaling pathways, the flexible nature of cross-talk 
may depend upon the primary mechanism activated in each context. However, a wide range of factors 
may also be involved, including additional crossroads. Through either a direct interface between 
pathways or shared target sets, signal integration might allow a simple interconnected system to 
generate an extraordinarily diverse output. The dramatic range of functions that these limited signals 
can create supports this paradigm. Studying its effects on the transcriptional output of integrated 
signals may be a useful approach to understanding the cross-talk. 
Extrapolating from the signal cross-talk paradigm, several features of the signaling hyper-network 
can be inferred. First, signaling pathways are remarkably interlinked and can integrate at the cellular 
and multicellular level through varied mechanisms. Second, cross-talk is of broad importance, 
impacting numerous signaling pathways, and the regulation of the cross-talk appears to be deeply 
disturbed in cancer. Third, cross-talk is flexible, generating differing consequences in different type of 
tumors or in different contexts. 
Thousands of positive and negative control feedback circuits inside the cells regulate the normal 
process of growth and proliferation. A disruption of this intracellular equilibrium is present in tumor 
cells and favors the activation of the anarchic proliferation and overproduction of growth factors that 
drive tumor development. Intracellular cross-talk occurs in every single solid tumor and is related to 
drug sensitivity and resistance, tumor escape and growth, prognosis, tumor behavior and multi-therapy 
resistance [135]. Several examples exist that demonstrate the role of intracellular cross-talk in solid 
tumors, such as those of the breast [136], lung [137], colorectal [138], and prostate [139]. 
In addition, cancer cells possess the adaptive ability to switch from one dominant growth factor 
pathway to another pathway under certain growth conditions to maintain proliferation and survival. In 
this sense, blocking one of the main signal transduction pathways may cause the tumor cells to switch 
their signal transduction to another non-blocked pathway to avoid the effects of the drug. 
The link between different signaling pathways may be present—Not only at the intracellular level 
but also at the extracellular level—The location of the receptors. Indeed, one of the most studied 
intracellular cross-talk mechanisms that occur in cancer is the link between the epidermal growth 
factor receptor (erbB/HER) family and the insulin-like growth factor receptor (IGFR).  
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4.3. Targeted Therapies are the Option of Choice 
The complexity of the aberrant signaling pathways in human cancer explains why interfering with 
only one single step of several that compose these pathways has not led to a sustained clinical response 
in cancer patients. Cancer cells have the ability to exploit diverse signaling pathways for growth 
advantage, cell survival and evasion of apoptosis and therefore by-pass the inhibition mediated by the 
administered drug. In fact, some of these alternative routes may even be facilitated by use of selective 
targeted agents and warrant interference at different stages to effectively reduce the tumor burden.  
Furthermore, different etiological factors and risk habits can result in distinct genetic and epigenetic 
alterations, which may trigger the activation of different signaling pathways that impact development 
and progression of cancer.  
The relatively limited effectiveness of traditional agents has led to the exploration of new, targeted 
drugs and to multi-targeted agents in cancer. Unfortunately, non-selective agents induce severe adverse 
events, and efficacy cannot currently be foreseen. The knowledge of cell biology and the mechanistic 
regulation of cancer are increasing and, together with the limited activity of conventional cytotoxic 
treatments, have allowed the development of new targeted therapies that thus far are not negligible and 
have shown a high percentage of disease stabilization and favorable safety profiles. 
Signaling pathways that do not play a role in carcinogenesis may carry other molecular 
characteristics that can potentially be targeted. 
Targeted therapy in oncology is based on the premise that tumor cells fundamentally rely on 
biological pathways to which drugs inhibiting those pathways can be applied. Biochemical studies of 
the signaling pathways deregulated in human cancer and target validation experiments have already 
culminated in the discovery and clinical application of small molecules with promising activity in 
cancer therapy. 
Human cancer stands out among other pathologies with the identification of biologically relevant 
pathways and drugs that inhibit critical pathway elements with significant clinical effects. Cancer is 
highly heterogeneous with a complex combination of different types of cells with diverse features in 
the center or the margin of the tumor. Expression patterns are very sensitive and reflect the cellular 
composition of the whole tumor. 
A fundamental paradigm of modern oncology is based on the discovery of the biologically relevant 
pathways that the cancer cell is dependent upon for survival. Drugs that inhibit one or more elements 
of the pathway are administered, ultimately leading to cancer cell death. This paradigm is dependent 
on multiple factors, including the identification of pathways that are truly critical for cell survival. 
Furthermore, drugs must effectively inhibit these pathway elements, and this inhibition must result in 
cell death.  
Cancer clearly comprises a diverse biologic array of diseases with different pathways that are 
relevant to tumor differentiation and growth. The investigation of gene and protein expression will 
hopefully provide insight that will lead to the optimization of specific therapies for specific tumors. 
Clinical testing of combination or sequential administration of targeted agents has begun, 
encompassing all possible combinations of active agents. This concept is predicated on the premise of 
modern oncology that combinations of non-cross-resistance agents can be combined for therapeutic 
benefit, such as an increased cure rate. The initial clinical results suggest intolerance to some 
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combinations, tolerance at less than full doses to others, and few able to be tolerated at full doses of 
both agents. Some promising clinical efficacy has been observed and is balanced against increased 
toxicity. For such therapy to advance in the treatment of human cancer, a combination must have 
greater clinical benefit than sequential monotherapy of the same agents. At present, combinations of 
targeted therapies remain investigational. 
To date, only the HIF/VEGF and mTOR pathways have been exploited for therapeutic purposes in 
RCC and, despite the sound preclinical rationale, targeting the EGFR pathway resulted in almost no 
clinical results. Despite the improvement made with agents targeting key molecular pathways, cure of 
RCC is still out of sight; furthermore, to date, those few cases of metastatic RCC patients who have 
been cured of their advanced disease have received immunotherapy.  
Much remains to be learned about signaling pathways as targets in human cancer, including 
inhibition with optimal risk/benefit ratios and the identification of novel pathways and targets. 
Translational investigation is needed to identify the molecular phenotype of response and resistance to 
each of the therapeutic agents. 
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